Log in

NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, Forecast & News

$1.81
-0.19 (-9.50 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$1.80
Now: $1.81
$1.99
50-Day Range
$1.19
MA: $2.23
$3.04
52-Week Range
$0.77
Now: $1.81
$5.40
Volume462,156 shs
Average Volume1.41 million shs
Market Capitalization$148.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Read More
Marinus Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.72 per share

Profitability

Net Income$-54,120,000.00

Miscellaneous

Employees28
Market Cap$148.91 million
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.


Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

How has Marinus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Marinus Pharmaceuticals' stock was trading at $1.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRNS shares have increased by 10.4% and is now trading at $1.81. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Marinus Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Marinus Pharmaceuticals.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Marinus Pharmaceuticals.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) posted its quarterly earnings results on Monday, March, 16th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. View Marinus Pharmaceuticals' earnings history.

What price target have analysts set for MRNS?

5 brokers have issued 1 year price targets for Marinus Pharmaceuticals' stock. Their forecasts range from $1.70 to $7.00. On average, they anticipate Marinus Pharmaceuticals' share price to reach $5.14 in the next year. This suggests a possible upside of 184.0% from the stock's current price. View analysts' price targets for Marinus Pharmaceuticals.

What are Wall Street analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (3/20/2020)
  • 2. LADENBURG THALM/SH SH analysts commented, "We find this is the right and not completely unexpected decision considering his enthusiasm in developing ganaxolone, his broad experience in companies and as an investor, as well as the need for strong stewardship at this time." (8/9/2019)
  • 3. Cantor Fitzgerald analysts commented, "Given the compelling Phase 2 data announced in CDD, market size potential in PPD (with positive interim data reported in 4Q18), and undervaluation relative to peers, we believe Marinus shares offer a compelling risk-reward profile. Valuation Summary We arrive at our 12-month PT of $22/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder." (5/1/2019)

Has Marinus Pharmaceuticals been receiving favorable news coverage?

Press coverage about MRNS stock has trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Marinus Pharmaceuticals earned a daily sentiment score of -5.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutMarinus Pharmaceuticals.

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a increase in short interest during the month of February. As of February 14th, there was short interest totaling 5,040,000 shares, an increase of 10.0% from the January 30th total of 4,580,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is currently 3.2 days. Approximately 10.9% of the company's stock are sold short. View Marinus Pharmaceuticals' Current Options Chain.

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the following people:
  • Mr. Edward F. Smith, VP, CFO, Treasurer & Sec. (Age 48)
  • Mr. Christopher Michael Cashman, CEO, Pres & Director (Age 62)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)
  • Dr. Scott Braunstein, Exec. Chairman (Age 56)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (11.03%), Boxer Capital LLC (8.91%), Granite Point Capital Management L.P. (5.01%), Alyeska Investment Group L.P. (4.09%), State Street Corp (1.70%) and Geode Capital Management LLC (1.30%). Company insiders that own Marinus Pharmaceuticals stock include Christopher Michael Cashman, Edward F Smith and Scott Braunstein. View institutional ownership trends for Marinus Pharmaceuticals.

Which major investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., State Street Corp, Bank of America Corp DE, and Barclays PLC. View insider buying and selling activity for Marinus Pharmaceuticals.

Which major investors are buying Marinus Pharmaceuticals stock?

MRNS stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Alyeska Investment Group L.P., Bain Capital Life Sciences Investors LLC, Asymmetry Capital Management L.P., Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., Nuveen Asset Management LLC, and Geode Capital Management LLC. View insider buying and selling activity for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $1.81.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $148.91 million. The biopharmaceutical company earns $-54,120,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Marinus Pharmaceuticals employs 28 workers across the globe. View additional information about Marinus Pharmaceuticals.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is http://www.marinuspharma.com/.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  357 (Thanks for Voting!)
Underperform Votes:  296 (Thanks for Voting!)
Total Votes:  653
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel